Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023
On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual adults using shared clinical decision-making. Informed use of these vaccines requires an understanding of RSV disease severity. To characterize RSV-associated severity, 5,784 adults aged ≥60 years hospitalized with acute respiratory illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20 U.S. states during February 1, 2022-May 31, 2023. Multivariable logistic regression was used to compare RSV disease severity with COVID-19 and influenza severity on the basis of the following outcomes: 1) standard flow (<30 L/minute) oxygen therapy, 2) high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV), 3) intensive care unit (ICU) admission, and 4) invasive mechanical ventilation (IMV) or death. Overall, 304 (5.3%) enrolled adults were hospitalized with RSV, 4,734 (81.8%) with COVID-19 and 746 (12.9%) with influenza. Patients hospitalized with RSV were more likely to receive standard flow oxygen, HFNC or NIV, and ICU admission than were those hospitalized with COVID-19 or influenza. Patients hospitalized with RSV were more likely to receive IMV or die compared with patients hospitalized with influenza (adjusted odds ratio = 2.08; 95% CI = 1.33-3.26). Among hospitalized older adults, RSV was less common, but was associated with more severe disease than COVID-19 or influenza. High disease severity in older adults hospitalized with RSV is important to consider in shared clinical decision-making regarding RSV vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
MMWR. Morbidity and mortality weekly report - 72(2023), 40 vom: 06. Okt., Seite 1083-1088 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Surie, Diya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 04.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.15585/mmwr.mm7240a2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362904758 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362904758 | ||
| 003 | DE-627 | ||
| 005 | 20240108141634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15585/mmwr.mm7240a2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM362904758 | ||
| 035 | |a (NLM)37796753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Surie, Diya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual adults using shared clinical decision-making. Informed use of these vaccines requires an understanding of RSV disease severity. To characterize RSV-associated severity, 5,784 adults aged ≥60 years hospitalized with acute respiratory illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20 U.S. states during February 1, 2022-May 31, 2023. Multivariable logistic regression was used to compare RSV disease severity with COVID-19 and influenza severity on the basis of the following outcomes: 1) standard flow (<30 L/minute) oxygen therapy, 2) high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV), 3) intensive care unit (ICU) admission, and 4) invasive mechanical ventilation (IMV) or death. Overall, 304 (5.3%) enrolled adults were hospitalized with RSV, 4,734 (81.8%) with COVID-19 and 746 (12.9%) with influenza. Patients hospitalized with RSV were more likely to receive standard flow oxygen, HFNC or NIV, and ICU admission than were those hospitalized with COVID-19 or influenza. Patients hospitalized with RSV were more likely to receive IMV or die compared with patients hospitalized with influenza (adjusted odds ratio = 2.08; 95% CI = 1.33-3.26). Among hospitalized older adults, RSV was less common, but was associated with more severe disease than COVID-19 or influenza. High disease severity in older adults hospitalized with RSV is important to consider in shared clinical decision-making regarding RSV vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Yuengling, Katharine A |e verfasserin |4 aut | |
| 700 | 1 | |a DeCuir, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yuwei |e verfasserin |4 aut | |
| 700 | 1 | |a Gaglani, Manjusha |e verfasserin |4 aut | |
| 700 | 1 | |a Ginde, Adit A |e verfasserin |4 aut | |
| 700 | 1 | |a Talbot, H Keipp |e verfasserin |4 aut | |
| 700 | 1 | |a Casey, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Mohr, Nicholas M |e verfasserin |4 aut | |
| 700 | 1 | |a Ghamande, Shekhar |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Kevin W |e verfasserin |4 aut | |
| 700 | 1 | |a Files, D Clark |e verfasserin |4 aut | |
| 700 | 1 | |a Hager, David N |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Harith |e verfasserin |4 aut | |
| 700 | 1 | |a Prekker, Matthew E |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Michelle N |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Amira |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Steingrub, Jay S |e verfasserin |4 aut | |
| 700 | 1 | |a Peltan, Ithan D |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Samuel M |e verfasserin |4 aut | |
| 700 | 1 | |a Leis, Aleda M |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Akram |e verfasserin |4 aut | |
| 700 | 1 | |a Hough, Catherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Bender, William S |e verfasserin |4 aut | |
| 700 | 1 | |a Duggal, Abhijit |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Jennifer G |e verfasserin |4 aut | |
| 700 | 1 | |a Qadir, Nida |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Steven Y |e verfasserin |4 aut | |
| 700 | 1 | |a Mallow, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Jennie H |e verfasserin |4 aut | |
| 700 | 1 | |a Exline, Matthew C |e verfasserin |4 aut | |
| 700 | 1 | |a Lauring, Adam S |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Nathan I |e verfasserin |4 aut | |
| 700 | 1 | |a Columbus, Cristie |e verfasserin |4 aut | |
| 700 | 1 | |a Vaughn, Ivana A |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Mayur |e verfasserin |4 aut | |
| 700 | 1 | |a Safdar, Basmah |e verfasserin |4 aut | |
| 700 | 1 | |a Halasa, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Chappell, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Grijalva, Carlos G |e verfasserin |4 aut | |
| 700 | 1 | |a Baughman, Adrienne |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Todd W |e verfasserin |4 aut | |
| 700 | 1 | |a Womack, Kelsey N |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jin H |e verfasserin |4 aut | |
| 700 | 1 | |a Swan, Sydney A |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Indrani |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Nathaniel M |e verfasserin |4 aut | |
| 700 | 1 | |a Ellington, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a McMorrow, Meredith L |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Emily T |e verfasserin |4 aut | |
| 700 | 1 | |a Self, Wesley H |e verfasserin |4 aut | |
| 700 | 0 | |a IVY Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t MMWR. Morbidity and mortality weekly report |d 1984 |g 72(2023), 40 vom: 06. Okt., Seite 1083-1088 |w (DE-627)NLM012594334 |x 1545-861X |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:40 |g day:06 |g month:10 |g pages:1083-1088 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15585/mmwr.mm7240a2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 40 |b 06 |c 10 |h 1083-1088 | ||